Lanadelumab

Author: Anoma Ranaweera, Medical Writer, Auckland, New Zealand. DermNet Editor in Chief: Adjunct A/Prof Dr Amanda Oakley, Dermatologist, Hamilton, New Zealand. Copy edited by Gus Mitchell. March 2019.


What is hereditary angioedema?

Hereditary angioedema is a rare, autosomal dominant disease associated with a deficiency or dysfunction of C1-esterase-inhibitor (C1-INH) activity. It causes spontaneous, recurrent, and potentially life-threatening swelling in various regions of the body, including the larynx.

Angioedema

What is lanadelumab?

Lanadelumab is a prescription biological medicine used in patients aged ≥ 12 years to prevent severe swelling attacks due to hereditary angioedema. It is the first monoclonal antibody available for hereditary angioedema.

Lanadelumab was approved by the US Food and Drug Administration (FDA) in August 2018, in Canada in September 2018, and by the European Commission (EC) in November 2018. Regulatory applications for marketing lanadelumab are also being considered in Australia. Lanadelumab is not currently available in New Zealand.

Landelumab is also called lanadelumab-flyo and has the trade name Takhzyro™ [Dyax Corp MA, USA].

How does lanadelumab work?

Lanadelumab is a fully human IgG1 monoclonal antibody (IgG1/κ-light chain) that provides targeted inhibition of plasma kallikrein, a critical regulator of hereditary angioedema attacks.

  • The activity of plasma kallikrein is regulated by the activity of C1-inhibitor.
  • C1-INH deficiency or dysfunction leads to uncontrolled increases in plasma kallikrein activity.
  • Plasma kallikrein is a protease that works by cleaving high molecular weight kininogen to generate the pro-inflammatory peptide bradykinin. Bradykinin is a potent vasodilator and increases vascular permeability — the cause of the swelling and pain associated with hereditary angioedema.
  • Lanadelumab occludes the proteolytic active site of plasma kallikrein, preventing the cleavage of kininogen to bradykinin.
  • Lanadelumab, therefore, decreases plasma kallikrein and bradykinin activity in patients with hereditary angioedema.

What is the indication for lanadelumab?

Lanadelumab is indicated to prevent recurrent attacks of hereditary angioedema in patients aged 12 years and older.

  • It is not intended for the treatment of acute hereditary angioedema attacks.
  • Treatment should be started under the supervision of a physician experienced in the management of patients with hereditary angioedema.

How is lanadelumab administered?

Lanadelumab may be self-administered or administered by a caregiver after training on subcutaneous injection technique by a healthcare professional.

  • The recommended starting dose is 300 mg lanadelumab by subcutaneous injection every 2 weeks.
  • The injection should be restricted to the recommended injection sites: the abdomen, the thighs, and the upper outer arms with the rotation of the injection site.
  • In patients who are free of attacks on treatment, the dose may be reduced to 300 mg every 4 weeks.
  • If a dose of lanadelumab is missed, the missed dose should be administered as soon as possible ensuring at least 10 days between doses.

Contraindications to lanadelumab

The main contraindication to lanadelumab is hypersensitivity to the active substance or to any of the excipients.

Warnings and precautions

Traceability

To improve the traceability of biological medicinal products, the name and the batch number of the administered lanadelumab should be clearly recorded.

Hypersensitivity reactions

Hypersensitivity reactions to lanadelumab have been observed. In case of a severe hypersensitivity reaction, the administration of lanadelumab must be stopped immediately and appropriate treatment initiated.

General

Lanadelumab is not intended for the treatment of acute attacks of hereditary angioedema. In the case of breakthrough angioedema, individualised treatment should be initiated with an approved rescue medication.

There are no available clinical data on the use of lanadelumab in hereditary angioedema patients with normal C1-INH activity.

Dosage modification

Patients with renal impairment

No studies have been conducted in patients taking lanadelumab who have severe renal impairment. Renal impairment is not expected to affect the exposure to lanadelumab or its safety profile. No dose adjustment is required in patients with renal impairment.

Patients with hepatic impairment

No dose adjustment is required in patients taking lanadelumab who have hepatic impairment. Hepatic impairment is not expected to affect exposure to lanadelumab. There are no studies in patients with moderate or severe hepatic impairment.

Older people

No dose adjustment is required for patients above 65 years of age because age is not expected to affect the exposure to lanadelumab.

Children

The safety and efficacy of lanadelumab in children aged less than 12 years have not been established. No data are available.

Use of lanadelumab in specific populations

Pregnant women

There are no available data on the use of lanadelumab in pregnant women to inform any drug associated risks. Monoclonal antibodies such as lanadelumab can cross the placenta during the third trimester of pregnancy with potentially harmful effects on the fetus. Studies in pregnant cynomolgus monkeys, treated with 33 times the maximum recommended dose for humans, revealed no evidence of harm to the developing fetus.

Nursing mothers

It is not known whether lanadelumab or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, mothers should discontinue nursing prior to using lanadelumab. Available pharmacokinetic data in cynomolgus monkeys have shown excretion of lanadelumab in milk at approximately 0.2% of the maternal plasma level.

Children

The safety and efficacy of lanadelumab in children < 12 years of age have not been established.

Older people

In clinical trials, no overall differences in safety or effectiveness have been observed between patients > 65 years of age and younger patients treated with lanadelumab.

Individuals of fertile age

The effect of lanadelumab on fertility has not been evaluated in humans. Lanadelumab had no effect on male or female fertility in cynomolgus monkeys.

What are potential drug interactions with lanadelumab?

No dedicated drug-drug interaction studies have been conducted with lanadelumab. Based on its characteristics, no pharmacokinetic interactions with co-administered medicinal products are expected.

Interaction with aPPT assay

  • Lanadelumab can increase the activated partial thromboplastin time (aPTT) due to an interaction with the aPTT assay.
  • Reagents used in the aPTT laboratory test initiate intrinsic coagulation through the activation of plasma kallikrein in the contact system.
  • Inhibition of plasma kallikrein by lanadelumab can increase aPTT in this assay.

What are the possible side effects of lanadelumab?

The most common side effects in patients receiving lanadelumab in clinical trials are described below.

> 10% incidence

At a dose of 300 mg every 2 weeks

  • Injection site reactions including pain, erythema and bruising (56%)
  • Upper respiratory tract infection (44%)
  • Headache (33%)
  • Myalgia (11%)

At a dose of 300 mg every 4 weeks

  • Injection site reactions (45%)
  • Upper respiratory tract infection (31%)
  • Headache (21%)

1–10% incidence

  • Increased alanine aminotransferase (ALT) and aspartate aminotransferase (AST) liver enzymes (2%)
  • Hypersensitivity (1%) — symptoms of a serious allergic reaction include urticaria, itching/swelling (especially of the face, tongue, and throat), severe dizziness, and difficulty breathing

At a dose of 300 mg every 2 weeks

  • Rash (4%)
  • Dizziness (4%)
  • Diarrhoea (4%)

At a dose of 300 mg every 4 weeks

  • Rash (10%)
  • Dizziness (10%)

Immunogenicity

Treatment with lanadelumab has been associated with the development of anti-drug antibodies in 11.9% of patients (10/84). All antibody titres were low. The anti-drug antibody response was transient in 20% of ADA positive subjects. 2.4% of lanadelumab-treated patients (2/84) tested positive for neutralising antibodies.

The development of anti-drug antibodies including neutralising antibodies against lanadelumab did not appear to adversely affect the pharmacokinetic and pharmacodynamic profiles or the clinical response.

New Zealand approved datasheets are the official source of information for these prescription medicines, including approved uses and risk information. Check the individual New Zealand datasheet on the Medsafe website.

See smartphone apps to check your skin.
[Sponsored content]

 

Related information

 

References

  • Riedl MA, Bernstein JA, Craig T et al. An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension. Clin Transl Allergy 2017; 7: 36. PubMed
  • Banerji A, Busse P, Shennak M et al. Inhibiting plasma kallikrein for hereditary angioedema prophylaxis. N Engl J Med 2017; 376: 717–728. PubMed
  • Banerji A, Riedl MA, Bernstein JA et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA 2018; 320: 2108–21. PubMed
  • Zuraw BL, Banerji A, Bernstein JA, et al. US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. J Allergy Clin Immunol Pract 2013; 1: 458–67. PubMed
  • Cicardi M, Aberer W, Banerji A, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy 2014; 69: 602–616. PubMed

On DermNet NZ

Other websites

  • Lanadelumab — US FDA prescribing information PDF [accessed January 2019]
  • Lanadelumab — Medscape data sheet
  • Lanadelumab — Product monograph Canada PDF [accessed February 2019]

Books about skin diseases

See the DermNet NZ bookstore.